Mark Bagarazzi

Mark Bagarazzi, MD is Chief Medical Officer and Senior Vice President of Clinical Development for Inovio Pharmaceuticals. Prior to joining Inovio, Dr Bagarazzi was Director of Worldwide Regulatory Affairs for Vaccines and Biologics at Merck Research Laboratories where he was responsible for the licensure of RotaTeq™ and lead the development team for Merck’s vaccine for the prevention of herpes zoster (shingles), ZOSTAVAX™. He was previously an assistant professor of pediatrics at Drexel College of Medicine where he served as director of the Pediatric HIV/AIDS program at St. Christopher’s Hospital for Children in Philadelphia and is currently a guest lecturer on vaccines and immunotherapeutics at the University of Pennsylvania, School of Medicine. Previously, he had been a guest lecturer at Johns Hopkins University. He is a patent holder and has authored or co-authored dozens of scientific papers, focused on the subject of DNA vaccines. He has been board certified in both Pediatrics and Pediatric Infectious Diseases and is a Fellow of the American Academy of Pediatrics. He received his training in pediatrics at St Christopher’s Hospital for Children and completed his fellowship in pediatric infectious diseases at Children’s Hospital of Philadelphia where he was an instructor at the University of Pennsylvania, School of Medicine. Bagarazzi holds a B.S. in electrical engineering magna cum laude from New Jersey Institute of Technology and received his MD degree with honors from New Jersey Medical School of the University of Medicine and Dentistry of New Jersey.